中肽生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
ILGF-003A
IGF-I (1-3)
Gly-Pro-Glu
Gly-Pro-Glu
Size：250mg
P1(RMB)：404
MW：301.3
One letter sequence：GPE
Molecular Formula：C12H19N3O6
Description：This N-terminal tripeptide of IGF-I facilitated the in vitro release of acetylcholine with a several hundredfold higher potency (10-10 - 10-6 M) than intact IGF-I (4 · 10-8 M), whereas truncated IGF-I lacking the tripeptide GPE, did not show any significant effect. This raises the possibility that GPE may be the active site of IGF-I. - Although the precise mode of action of GPE is still unknown, another study suggests that local administration of GPE is neuroprotective after brain HI injury via glial cells. In addition, systemic administration of GPE showed a more widespread neuroprotective effect. Therefore, GPE may represent a complementary pathway for central and systemic IGF-1's antiapoptotic effects.
Literature Reference：L.Nilsson-Hakansson et al., NeuroReport, 4, 1111 (1993) S.V.Sizonenko et al., Brain Res., 922, 42 (2001) J.Guan et al., Neuropharmacology, 47, 892 (2004) D.Aguado-Llera et al., Neuroreport, 15, 1978 (2004) S.Shapira et al., Neurosci. Lett., 454, 53 (2009)
Cas：32302-76-4
P1(RMB)：404
MW：301.3
One letter sequence：GPE
Molecular Formula：C12H19N3O6
Description：This N-terminal tripeptide of IGF-I facilitated the in vitro release of acetylcholine with a several hundredfold higher potency (10-10 - 10-6 M) than intact IGF-I (4 · 10-8 M), whereas truncated IGF-I lacking the tripeptide GPE, did not show any significant effect. This raises the possibility that GPE may be the active site of IGF-I. - Although the precise mode of action of GPE is still unknown, another study suggests that local administration of GPE is neuroprotective after brain HI injury via glial cells. In addition, systemic administration of GPE showed a more widespread neuroprotective effect. Therefore, GPE may represent a complementary pathway for central and systemic IGF-1's antiapoptotic effects.
Literature Reference：L.Nilsson-Hakansson et al., NeuroReport, 4, 1111 (1993) S.V.Sizonenko et al., Brain Res., 922, 42 (2001) J.Guan et al., Neuropharmacology, 47, 892 (2004) D.Aguado-Llera et al., Neuroreport, 15, 1978 (2004) S.Shapira et al., Neurosci. Lett., 454, 53 (2009)
Cas：32302-76-4
